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Abstract 
The reactions of [Ru(NO)Cl5]
2− with glycine (Gly), L-alanine (L-Ala), L-valine (L-
Val), L-proline (L-Pro), D-proline (D-Pro), L-serine (L-Ser), L-threonine (L-Thr), and  
L-tyrosine (L-Tyr) in n-butanol or n-propanol afforded eight novel complexes of the 
general formula [RuCl3(AA−H)(NO)]
−, where AA = Gly, L-Ala, L-Val, L-Pro, D-Pro, 
L-Ser, L-Thr, L-Ser and L-Tyr, respectively. The compounds were characterized by 
elemental analysis, electrospray ionization mass spectrometry (ESI-MS), 1H NMR, 
UV−vis, ATR IR spectroscopy, cyclic voltammetry and X-ray crystallography. X-ray 
crystallography studies have revealed that in all cases the same isomer type (from 
three theoretically possible), has been isolated, namely mer(Cl), trans(NO,O)-
[RuCl3(AA−H)(NO)], as it was also recently reported for osmium analogs with Gly, 
L-Pro and D-Pro (see Z. Anorg. Allg. Chem. 2013, 639, 1590−1597). Compounds 1, 4, 
5 and 8 were investigated with regard to their stability in aqueous solution and 
reactivity towards sodium ascorbate by ESI-MS. In addition, cell culture experiments 
in three human cancer cell lines, namely A549 (nonsmall cell lung carcinoma), CH1 
(ovarian carcinoma) and SW480 (colon adenocarcinoma) have been performed and 
the results discussed in conjunction with the lipophilicity of compounds. 
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Introduction 
Nitric oxide plays important roles in biochemical processes,1 and, in particular, in 
progression of human tumors.2 The antimetastatic activity of NAMI-A, an 
investigational drug in phase II clinical trials,3 was suggested to be related to its 
interaction with NO in vivo.4 Given the importance of NO as a noninnocent ligand in 
coordination chemistry,5 the occurrence of structural trans effects (STEs), the role of 
the metal-nitrosyl unit as a reaction mediator or regulator of geometry around the 
metal ion,6 as well as linkage isomerization of the N- and O-bound nitrosyl ligand,7 
surprisingly little is known about the reactivity of ruthenium(II)- and osmium(II)-
nitrosyl compounds with respect to amino acids. Although a few ruthenium-nitrosyl 
complexes with amino acids and related ligands have been reported in the literature, 
e.g., K[Ru(Gly)(OH)3NO],
8 K[Ru(L-Ala)(OH)3NO],
9 [RuCl2(L-His)(NO)],
10 
[RuCl2(L-Met)(NO)]
11 and (C2H5)4N[RuCl3(pyca)(NO)],
12 where pycaH = 2-
pyridinecarboxylic acid, their antiproliferative activity remains unknown. All this 
prompted us to continue our recently initiated study13 on the interaction of 
[MCl5(NO)]
2− with different amino acids as a benchmark for further investigation of 
the reactivity of ruthenium and osmium nitrosyl complexes with azole heterocycles 
towards amino acids (AA). 
 
Moreover, we reported recently on the synthesis of two series of transition metal 
complexes, namely (cation)[cis-MCl4(Hazole)(NO)] and (cation)[trans-
MCl4(Hazole)(NO)], where M = Ru, Os and Hazole = 1H-indazole, 1H-pyrazole, 1H-
imidazole or 1H-benzimidazole. Ruthenium and osmium analogs showed a striking 
difference in antiproliferative activity in three human cancer cell lines A549 
(nonsmall cell lung carcinoma), CH1 (ovarian carcinoma) and SW480 (colon 
adenocarcinoma).14,15 These results were in strong contrast to previous comparative 
studies on homologous ruthenium and osmium complexes (with metal ion in different 
oxidation states) showing either similar activities16,17 or much smaller 
differences18,19,20 than those observed for compounds reported in ref. 15. We are now 
trying to find out whether their behavior towards amino acids can provide an 
explanation for their different antiproliferative activity. Amino acids are the basic 
units of proteins and the most important low-molecular-weight biological ligands. 
They are major ingredients of the media used in cell culture experiments.21 In 
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addition, reactions with amino acids are likely to be involved in speciation of metal 
complexes during biotransformation in the body. Knowledge about these reactions 
will therefore help in elucidating the species delivered into the cell and in better 
understanding the mechanisms of drug metabolisation or detoxification.22 For 
example, a [(Pt(L-Met)2] species was isolated from the urine of cancer patients treated 
with cisplatin. This is one of the few known metabolites of the drug.23 
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Herein we report on the synthesis of eight new ruthenium(II)-nitrosyl complexes with 
Gly, L-Ala, L-Val, L-Pro, D-Pro, L-Ser, L-Thr and L-Tyr (Chart 1), their X-ray 
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diffraction structures, spectroscopic and electrochemical properties, lipophilicity, 
behavior in aqueous solution and antiproliferative activity in human cancer cell lines 
in vitro. The latter was compared to that of osmium-nitrosyl complexes with Gly (1*), 
L-Pro (4*) and D-Pro (5*). 
Experimental Section 
Materials. The starting compounds Na2[RuCl5NO]∙6H2O and (nBu4N)2[RuCl5NO] 
were synthesized as previously reported in the literature.24 RuCl3·H2O was purchased 
from Johnson Matthey, sodium nitrite (97%), tetrabutylammonium chloride (97%), L-
Thr, L-Ala and Gly (99%) were from Sigma-Aldrich. L-Ser was from Serva, L-Pro 
(99%) and D-Pro (99%) were from Alfa Aesar and L-Tyr (99%), formic acid and 
sodium ascorbate were from Fluka. All chemicals were used without further 
purification. Methanol (HPLC grade, Fisher) and ultra-pure water (18.2 M, 
Advantage A10, 185 Ultrapure Water System, Millipore, France) were used for ESI-
MS study. 
 
Synthesis of Complexes 
(nBu4N)[RuCl3(GlyH)(NO)] (1). A mixture of Na2[RuCl5NO]∙6H2O (400 mg, 0.86 
mmol), nBu4NCl (362 mg, 1.31 mmol) and Gly (121 mg, 1.61 mmol) was refluxed in 
n-butanol (10 mL) for 1.5 h. The solution was allowed to cool to room temperature. 
The separated salt was filtered off. The solution was transferred into a beaker. Dark 
red crystals formed after several days were filtered off and washed with water/ethanol 
1:3 (4 mL), diethyl ether (4 mL) and dried in vacuo. Yield: 75 mg, 15.5%. Anal. 
Calcd for C18H40Cl3N3O3Ru (M = 553.96 g/mol): C, 39.03; H, 7.28; N, 7.59. Found: 
C, 38.77; H, 6.96; N, 7.43. ESI-MS in MeOH (negative): ESI-MS in MeOH 
(negative): m/z 312.72 [RuCl3NO(Gly − H)]
− (mtheor = 312.83), 274.70 [RuCl2NO(Gly 
– 2H)]− (mtheor = 274.86), 238.71 [RuClNO(Gly − 3H)]
− (mtheor = 238.88). IR, cm
–1: 
886, 1160, 1301, 1490, 1669 (vs) as(COO
), 1862 (vs) (NO), 2955 (m) (CH), 3124 
(m) s(NH2) and 3193 (m) as(NH2). UV−vis (buffer), λmax, nm (ε, M
–1cm–1): 279 
(1790), 453 (104). 1H NMR (500.32 MHz, DMSO-d6): δ 0.95 (t, 12HD, J = 7.5 Hz), 
1.32 (sxt, 8HC, J = 7.3 Hz), 1.58 (qui, 8HB, J = 7.8 Hz), 3.17 (m, 8HA, J = 8.2 Hz), 
3.36 (t, J = 6.5 Hz, 2H, H2), 5.89 (s, 2H, H3) ppm. For assignment of proton 
resonances see atom numbering in Chart 1. 
 
 6 
(nBu4N)[RuCl3(L-AlaH)(NO)] (2). A mixture of Na2[RuCl5NO]∙6H2O (400 mg, 
0.86 mmol), nBu4NCl (450 mg, 1.62 mmol) and L-Ala (115 mg, 1.29 mmol) was 
refluxed in n-butanol (10 mL) for 1.5 h. The solvent was removed under reduced 
pressure and the remaining oil was dried in vacuo. Water (7 mL) was added. The 
solution was decanted into a beaker and allowed to stand at room temperature. Five 
days later orange crystals were filtered off and a second fraction was collected two 
days later. The product was washed with water/ethanol 1:1 (4 mL), diethyl ether (4 
mL) and dried in vacuo. Yield: 102 mg, 21.0%. Anal. Calcd for C19H42Cl3N3O3Ru (M 
= 567.98 g/mol): C, 40.18; H, 7.45; N, 7.40. Found: C, 40.15; H, 7.72; N, 7.05. ESI-
MS in MeOH (negative): m/z 326.69 [RuCl3NO(L-Ala − H)]
− (mtheor = 326.85), 
288.68 [RuCl2NO(L-Ala − 2H)]
− (mtheor = 288.87), 252.68 [RuClNO(L-Ala − 3H)]
− 
(mtheor = 252.89). IR, cm
–1: 873, 1181, 1266, 1224, 1470, 1577, 1666 (vs) as(COO
), 
1858 (vs) (NO), 2874, 2960 (CH), 3120 (m) s(NH2)  and 3190 (m) as(NH2). 
UV−vis (buffer), λmax, nm (ε, M
–1cm–1): 279 (1857), 453 (104). 1H NMR (500.32 
MHz, DMSO-d6): δ 0.95 (t, 12HD, J = 7.4 Hz), 1.32 (m, 12H, 8HC, 3H4), 1.58 (qui, 
8HB, J = 7.8 Hz), 3.17 (t, 8HA J = 8.2 Hz), 3.59 (qua, 1H, H2, J = 7.3 Hz), 5.28 (m, 
1H, H3´) and 6.39 (m, 1H, H3´´) ppm.  
 
(nBu4N)[RuCl3(L-ValH)(NO)] (3). A mixture of Na2[RuCl5NO]∙6H2O (400 mg, 
0.86 mmol), nBu4NCl (450 mg, 1.62 mmol) and L-Val (151 mg, 1.29 mmol) was 
refluxed in n-butanol (10 mL) for 2 h. The solvent was removed under reduced 
pressure and the remaining oil was dried in vacuo. Water (7 mL) was added. The 
solution was decanted into a beaker and allowed to stand at room temperature. Seven 
days later orange crystals formed were filtered off, washed with water/ethanol 1:1 (4 
mL), diethyl ether (4 mL) and dried in vacuo. Yield: 179 mg, 35.0%. Anal. Calcd for 
C21H46Cl3N3O3Ru∙0.5H2O (M = 605.05 g/mol): C, 41.69; H, 7.83; N, 6.94. Found: C, 
41.69; H, 8.14; N, 6.73. ESI-MS in MeOH (negative): m/z 355 [RuCl3NO(L-Val − 
H)]− (mtheor = 354.88), 317 [RuCl2NO(L-Val−2H)]
−, 281 [RuClNO(L-Val−3H]−. IR, 
cm–1: 806, 894, 1012, 1180, 1299, 1372, 1467, 1663 (vs) as(COO
), 1852 (vs) (NO), 
2878, 2962 (m) (CH) and 3187 (m) (NH2). UV−vis (buffer), λmax, nm (ε, M
–1cm–1): 
279 (1883), 453 (104). 1H NMR (500.32 MHz, DMSO-d6): δ 0.86 (d, 3H, H6, J = 7.9 
Hz), 0.95 (t, 12HD, J = 7.4 Hz), 0.99 (d, 3H, H5 J = 7.9), 1.32 (sxt, 8HC, J = 7.4 Hz), 
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1.58 (qui, 8HB, J = 7.8 Hz),2.19 (m, 1H, H4), 3.17 (t, 8HA J = 8.2 Hz), 3.44 (m, 1H, 
H2), 4.67 (m, 1H, H3´), 6.44 (m, 1H, H3´´) ppm.  
 
(nBu4N)[RuCl3(L-ProH)(NO)] (4). A mixture of (nBu4N)2[RuCl5NO] (350 mg, 
0.44 mmol) and L-Pro (76 mg, 0.66 mmol) was refluxed in n-butanol (6 mL) for 3.5 h. 
The solvent was removed under reduced pressure. The remaining oil was dissolved in 
water (5 mL). The solution was transferred into a beaker and allowed to stand at room 
temperature. Orange crystals formed were filtered off and a second fraction was 
collected after 24 h. The product was washed with water/ethanol 1:1 (4 mL), diethyl 
ether (4 mL) and dried in vacuo. Yield: 94 mg, 36%. Anal. Calcd for 
C21H43Cl3N3O3Ru (M = 593.01 g/mol): C, 42.53; H, 7.31; N, 7.09. Found: C, 42.48; 
H, 7.37; N, 6.78. ESI-MS in MeOH (negative): m/z 352.71 [RuCl3NO(L-Pro − H)]
− 
(mtheor = 352.86), 314.76 [RuCl2NO(L-Pro − 2H)]
− (mtheor = 314.87), 278.69 
[RuClNO(L-Pro − 3H)]− (mtheor = 278.91). IR, cm
–1: 740, 883, 1353, 1464, 1644, 1647 
(vs) as(COO
), 1845 (vs) (NO), 2874 and 2960 (m) (CH), 3101 (m) s(NH2) and 
3169 (m) as(NH2). UV−vis (buffer), λmax, nm (ε, M
–1cm–1): 279 (1981), 253 (104). 1H 
NMR (500.32 MHz, DMSO-d6): δ 0.95 (t, 12HD, J = 7.4 Hz), 1.32 (sxt, 8HC, J = 7.4 
Hz), 1.58 (qui, 8HB, J = 7.8 Hz),1.69 (m, 1H, H5´), 1.85 (m, 2H, H6´, H5´´), 2.05 (m, 
1H, H6´´), 2.87 (m, 1H, H4´), 3.17 (t, 8HA J = 8.2 Hz), 3.42 (m, 1H, H4´´), 3.88 (qua, 
1H, H2, J = 7.1 Hz), 7.08 (m, 1H, H3) ppm. 
 
(nBu4N)[RuCl3(D-ProH)(NO)] (5). A mixture of Na2[RuCl5NO]·6H2O (400 mg, 
0.86 mmol), nBu4NCl (450 mg, 1.62 mmol) and D-Pro (148 mg, 1.29 mmol) was 
refluxed in n-propanol (10 mL) for 2 h. The solvent was removed under reduced 
pressure. Water (7 mL) was added to the residue. The solution was decanted into a 
beaker and allowed to stand at room temperature. Orange crystals formed were 
filtered off after 72 h, washed with water/ethanol 1:1 (4 mL), diethyl ether (4 mL) and 
dried in vacuo. Yield: 175 mg, 34.0%. Anal. Calcd for C21H43Cl3N3O3Ru∙0.75H2O (M 
= 606.52 g/mol): C, 41.54; H, 7.33; N, 6.92. Found: C, 41.70; H, 7.68; N, 7.07. ESI-
MS in MeOH (negative): m/z 351 [RuCl3NO( D-Pro)]
−, 279 [RuClNO(D-Pro)−2HCl]−. 
IR, cm–1: 740, 883, 1353, 1464, 1644, 1647 (vs) as(COO
), 1845 (vs) (NO), 2874,  
2960 (m) (CH), 3198 (m) (NH2). UV−vis (buffer), λmax, nm (ε, M
–1cm–1): 279 
(1846), 253 (90). 1H NMR (500.32 MHz, DMSO-d6): δ 0.95 (t, 12HD, J = 7.4 Hz), 
 8 
1.32 (sxt, 8HC, J = 7.4 Hz), 1.58 (qui, 8HB, J = 7.8 Hz),1.69 (m, 1H, H5´), 1.85 (m, 
2H, H6´, H5´´), 2.05 (m, 1H, H6´´), 2.87 (m, 1H, H4´), 3.17 (t, 8HA J = 8.2 Hz),3.42 (m, 
1H, H4´´), 3.88 (qua, 1H, H2, J = 7.1 Hz), 7.08 (m, 1H, H3) ppm. 
 
(nBu4N)[RuCl3(L-SerH)(NO)] (6). A mixture of Na2[RuCl5NO]∙6H2O (400 mg, 
0.86 mmol), nBu4NCl (450 mg, 1.62 mmol) and L-Ser (137 mg, 1.29 mmol) was 
refluxed in n-butanol (10 mL) for 1.5 h. The solvent was removed under reduced 
pressure and the remaining oil was dried in vacuo. The remaining oil was dissolved in 
water (10 mL). The solution was decanted into a beaker and allowed to stand at room 
temperature. Four days later orange crystals were filtered off, washed with 
water/ethanol 1:1 (4 mL), diethyl ether (4 mL) and dried in vacuo. Yield: 111 mg, 
22.0%. Anal. Calcd for C19H42Cl3N3O4Ru (M = 583.98 g/mol): C, 39.08; H, 7.25; N, 
7.20. Found: C, 39.30; H, 6.90; N, 6.93. ESI-MS in MeOH (negative): m/z 342.70 
[RuCl3NO(L-Ser − H)]
− (mtheor = 342.84), 304.70 [RuCl2NO(L-Ser − 2H)]
− (mtheor = 
304.87). IR, cm–1: 878, 1070, 1369, 1477, 1644 (vs) as(COO
), 1855 (vs) (NO), 
2875, 2956 (m) a(CH), 3120 (m) s(NH2), 3190 (m) as(NH2) and 3448 (m) s(OH). 
UV−vis (buffer), λmax, nm (ε, M
–1cm–1): 279 (1721), 453 (87). 1H NMR (500.32 MHz, 
DMSO-d6): δ 0.95 (t, 12HD, J = 7.4 Hz), 1.32 (sxt, 8HC, J = 7.4 Hz), 1.58 (qui, 8HB, J 
= 7.8 Hz), 3.17 (t, 8HA J = 8.2 Hz), 3.59 (m, 1H, H4´), 3.75 (m, 1H, H4´´), 4.98 (m, 1H, 
H3´), 5.05 (t, 1H, H2, J = 5.35 Hz), 6.45 (m, 1H, H3´´) ppm.  
 
(nBu4N)[RuCl3(L-ThrH)(NO)] (7). A mixture of Na2[RuCl5NO]∙6H2O (400 mg, 
0.86 mmol), nBu4NCl (450 mg, 1.62 mmol) and L-Thr (154 mg, 1.29 mmol) was 
refluxed in n-butanol (10 mL) for 1.5 h. The solvent was removed under reduced 
pressure and the remaining oil was dried in vacuo. The remaining oil was dissolved in 
water (10 mL). The solution was decanted into a beaker and allowed to stand at room 
temperature. Six days later orange crystals were filtered off, washed with 
water/ethanol 1:1 (4 mL), diethyl ether (4 mL) and dried in vacuo. Yield: 88 mg, 
17.0%. Anal. Calcd for C20H44Cl3N3O4Ru (M = 598.01 g/mol): C, 40.17; H, 7.42; N, 
7.03. Found: C, 40.02; H, 7.81; N, 6.78. ESI-MS in MeOH (negative): m/z 356.71 
[RuCl3NO(L-Thr − H)]
− (mtheor = 356.86), 318.72 [RuCl2NO(L-Thr − 2H)]
− (mtheor = 
318.88). IR, cm–1: 592, 742, 890, 1066, 1173, 1257, 1372, 1459, 1642 (vs) as(COO
), 
1849 (vs) (NO), 2875, 2966 (m) (CH), 3233 (m) (NH2) and 3440 (m) (OH). 
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UV−vis (buffer), λmax, nm (ε, M
–1cm–1): 279 (1761), 453 (89). 1H NMR (500.32 MHz, 
DMSO-d6): δ 0.95 (t, 12HD, J = 7.4 Hz), 1.17 (d, 3H; H5, J = 6.75), 1.32 (sxt, 8HC, J = 
7.4 Hz), 1.58 (qui, 8HB, J = 7.8 Hz), 3.17 (t, 8HA, J = 8.2 Hz), 4.15 (m, 1H, H4), 4.92 
(m, 1H, H3´), 5.16 (d, 1H, H2, J = 5.33), 6.46 (m, 1H, H3´´) ppm.  
 
(nBu4N)[RuCl3(L-TyrH)(NO)] (8). A mixture of Na2[RuCl5NO]·6H2O (500 mg, 
1.08 mmol), nBu4NCl (598 mg, 2.16 mmol) and L-Tyr (294 mg, 1.62 mmol) was 
refluxed in n-butanol (10 mL) for 2 h. The solution was allowed to cool down to room 
temperature, filtered and transferred into an Erlenmeyer flask. After 12 days dark-red 
crystals were filtered off, washed with water (5 mL), ethanol (5 mL), diethyl ether (5 
mL) and dried in vacuo. Yield: 274 mg, 38%. Anal. Calcd for C24H44Cl3N3O4Ru (M = 
660.08 g/mol): C, 45.49; H, 7.02; N, 6.37. Found: C, 45.33; H, 6.85; N, 6.12. ESI-MS 
in MeOH (negative): m/z 418.73 [RuCl3NO(L-Tyr − 2H)]
− (mtheor = 418.87), 380.77 
[RuCl2NO(L-Tyr − 2H]
− (mtheor = 380.90), 344.78 [RuClNO(L-Tyr − 3H]
− (mtheor = 
344.92). IR, cm–1: 740, 827, 1183, 1270, 1366, 1466, 1641 (vs) as(COO
), 1885 (vs) 
(NO), 2962 m (CH), 3101 (m) s(NH2) and 3169 (m) as(NH2). UV−vis (buffer), 
λmax, nm (ε, M
–1cm–1): 279 (2109), 453 (99). 1H NMR (500.32 MHz, DMSO-d6): δ 
0.95 (t, 12HD, J = 7.4 Hz), 1.32 (sxt, 8HC, J = 7.4 Hz), 1.58 (qui, 8HB, J = 7.8 
Hz),2.96 (m, 2H, H4´, H4´´), 3.17 (t, 8HA J = 8.2 Hz), 3.75 (m, 1H, H2), 4.71 (m, 1H 
H3´), 6.41 (m, 1H, H3´´),6.69 (d, 2H, H5, J = 7.4 Hz), 7.09 (d, 2H, H5, J = 8.4 Hz), 9.22 
(s, 1H, H7) ppm. 
 
Physical measurements. 1H NMR spectra were recorded on Bruker Avance III 
instrument (Ultrashiled Magnet) at 500.13 MHz at room temperature. DMSO-d6 was 
used as solvent. Standard pulse programs were applied. 1H chemical shifts were 
measured relatively to the residual solvent peaks. Hydrolytic stability of complex 8 in 
20 mM phosphate buffer at pH 7.4,0.1 M (KCl) ionic strength and in pure water, both 
containing 10% D2O, was followed by recording 
1H NMR spectra over 24 h. Complex 
concentration was 1.0 mM. Watergate water suppression program and DSS internal 
standard were used. ATR-IR spectra were measured on a Bruker Vertex spectrometer. 
D7.4 values were determined by the traditional shake-flask method in n-
octanol/buffered aqueous solution at pH 7.4 (HEPES buffer) at 298.0 ± 0.2 K as 
described previously.25 In the case of the complexes of L-Ala (2) and L -Val (3) the 
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D7.4 values were determined in the presence of 0.1 M KCl as well. Two parallel 
experiments were performed for each sample. The complexes were dissolved at 0.3 
mM in the n-octanol pre-saturated aqueous solution of the buffer (0.02 M). The 
aqueous solutions and n-octanol with 1:1 phase ratio were gently mixed with 360° 
vertical rotation for 3 h to avoid the emulsion formation, and the mixtures were 
centrifuged at 5000 rpm for 3 min by a temperature controlled centrifuge at 298 K. 
After separation, UV spectra of the complexes in the aqueous phase were compared to 
those of the original aqueous solutions, and D7.4 values were calculated as the mean of 
[Absorbance (original solution) / Absorbance (aqueous phase after separation) – 1] 
obtained in the region of λ ~ (250  290 nm).  
 
CD and UV−vis spectra under physiological conditions (0.02 M phosphate buffer, pH 
7.40 with 0.1 M KCl) were recorded on a Jasco J-815 spectrometer in an optical cell 
of 2 cm path length (l) in the wavelength interval from 220 to 600 nm. The analytical 
concentration for the CD measurement of the complexes was 50 µM in aqueous 
solution. CD data are given as the differences in molar absorptivities between left and 
right circularly polarized light, based on the concentration of the ligand (Δε = ΔA / l/ 
ccomplex). The concentrations for the UV−vis measurements amounted 403 (1), 401 (4), 
401 (5), 400 (8), 399 (3), 401 (2), 403 (7) and 401 (6) µM.  
 
ESI-MS measurements for the characterization of the complexes were carried out with 
a Bruker Esquire 3000 instrument; the samples were dissolved in methanol.  
Cyclic voltammetry measurements were performed at room temperature using an 
AMEL 7050 all-in one potentiostat. The concentrations amounted 1.52.5 mM, the 
samples were dissolved in acetonitrile and 0.1 to 0.2 M nBu4N[BF4] was added as 
supporting electrolyte. Further a 3 mm GC (glassy carbon electrode) working 
electrode, a Pt auxiliary electrode and a SCE (saturated calomel electrode) reference 
electrode were used. The same electrode types were used for coulometry. In this case, 
the compartment of auxiliary electrode was separated from the study compartment. 
Ferrocene was used as an internal standard. 
 
Crystallographic Structure determination. X-ray diffraction measurements were 
performed on a Bruker X8 APEXII CCD diffractometer. Single crystals were 
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positioned at 40 mm from the detector and 1348, 1526, 1100, 2183, 961, 2191, 1606 
and 1391 frames were measured, each for 30, 30, 80, 20, 10, 60, 30 and 30 s over 1 
(or 0.5° for 4) scan width for 18, respectively. The data were processed using SAINT 
software.26 Crystal data, data collection parameters, and structure refinement details 
are given in Tables 1 and 2. The structures were solved by direct methods and refined 
by full-matrix least-squares techniques. Non-hydrogen atoms were refined with 
anisotropic displacement parameters. H atoms were inserted in calculated positions 
and refined with a riding model. Two carbon atoms C5 and C6 in the 
tetrabutylammonium cation in 1 were found to be disordered over 3 positions with site 
occupation factors (s.o.f.) 0.4:0.4:0.2, while C20, C21 and C22 in one of six 
crystallographically independent TBA cations in 2 over two positions with s.o.f. 
0.5:0.5. In complex 4 the C2 atom of the prolinic ring and atoms C6 and C8 of L-Ser 
in one crystallographically independent complex anion in 6 were found to be 
disordered over two positions with populations 0.8:0.2. The carbon atoms C12, C13, 
C16, C17, C21 and C24, C25 in the TBA cation in 8 were found to be disordered over 
2 positions with s.o.f. 0.6:0.4. The disorder was resolved by using restraints SADI and 
EADP implemented in SHELXL. The following computer programs and hardware 
were used: structure solution, SHELXS-97 and refinement, SHELXL-9727; molecular 
diagrams, ORTEP28; computer, Intel CoreDuo. 
 
Mass Spectrometry. The stability of four compounds, namely 1, 4, 5 and 8 in 
aqueous solution and in the presence of 4 equiv sodium ascorbate was investigated 
using an AmaZon SL ESI ion trap mass spectrometer (Bruker Daltonics GmbH, 
Bremen, Germany). For this purpose, the compounds were diluted from 400 µM stock 
solution (1% DMSO) to 50 µM in water and in the presence of 200 µM sodium 
ascorbate. The solutions were incubated at 37 °C in the dark and samples were 
measured after 0.5, 1, 2, 6 and 24 h after a second dilution step to 5 µM of the metal 
compound. The samples were introduced by direct infusion into the mass 
spectrometer at 280 µL/h and mass spectra were recorded over 0.5 min and averaged. 
Typical experimental conditions were as follows: HV capillary ±4.5 kV, dry temp 
180 °C, nebulizer 8 psi, dry gas 6 L/min, RF level 77%, trap drive 57.6, average 
accumulation time 25 ms (negative ion mode) and 120 µs (positive ion mode). Mass 
spectra were acquired and processed using ESI Compass 1.3 and DataAnalysis 4.0 
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(Bruker Daltonics GmbH, Bremen, Germany). The theoretically most abundant signal 
of isotopic pattern is annotated. 
 
Antiproliferative activity. CH1 cells (human ovarian carcinoma) were a generous 
gift from Lloyd R. Kelland, CRC Centre for Cancer Therapeutics, Institute of Cancer 
Research, Sutton, UK. SW480 (human adenocarcinoma of the colon) and A549 
(human nonsmall cell lung cancer) cells were kindly provided by Brigitte Marian 
(Institute of Cancer Research, Department of Medicine I, Medical University of 
Vienna, Austria). All cell culture media and reagents were purchased from Sigma-
Aldrich Austria and plastic ware from Starlab Germany. Cells were grown in 75 cm² 
culture flasks as adherent monolayer cultures in Minimum Essential Medium (MEM) 
supplemented with 10% heat-inactivated fetal calf serum, 1 mM sodium pyruvate, 4 
mM L-glutamine and 1% non-essential amino acids (from 100x ready-to-use stock). 
Cultures were maintained at 37 °C in humidified atmosphere containing 95% air and 
5% CO2. 
 
Cytotoxic effects of the test compounds were determined by means of a colorimetric 
microculture assay [MTT assay; MTT = 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-
2H-tetrazolium bromide] as described previously.13 Cells were harvested from culture 
flasks by trypsinization and seeded by using a pipetting system (Biotek Precision XS 
Microplate Sample Processor) in densities of 1 × 103 (CH1), 2 × 103 (SW480) and 3 × 
103 (A549) in 100 μL/well aliquots in 96-well microculture plates. For 24 h, cells 
were allowed to settle and resume proliferation. Test compounds were then dissolved 
in DMSO, diluted in complete culture medium and added to the plates where the final 
DMSO content did not exceed 0.5%. After 96 h of drug exposure, the medium was 
replaced with 100 μL/well of a 1:7 MTT/RPMI 1640 mixture (MTT solution, 5 
mg/mL of MTT reagent in phosphate-buffered saline; RPMI 1640 medium, 
supplemented with 10% heat-inactivated fetal bovine serum and 4 mM L-glutamine), 
and plates were incubated for further 4 h at 37 °C. Subsequently, the solution was 
removed from all wells, and the formazan crystals formed by viable cells were 
dissolved in 150 μL of DMSO per well. Optical densities at 550 nm were measured 
with a microplate reader (Biotek ELx808) by using a reference wavelength of 690 nm 
to correct for unspecific absorption. The quantity of viable cells was expressed 
relative to untreated controls, and 50% inhibitory concentrations (IC50) were 
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calculated from concentration-effect curves by interpolation. Evaluation is based on 
means from three independent experiments. 
  
Results and Discussion 
We were interested in the study of the reactions of ruthenium-nitrosyl complexes with 
all amino acids except two already reported in the literature with L-His and L-Met,10,11 
isolation of the resulted products and testing antiproliferative activity of all prepared 
products, including [RuCl2(L-HisH)(NO)] and [RuCl2(L-MetH)(NO)], reported 
previosly. Amino acids are potential biological ligands for ruthenium anticancer 
drugs. The interactions with amino acids deserve to be investigated, as they can help 
in elucidating the underlying mechanism of their antitumor activity. These reactions 
and the biological effects of the resulting species are still little understood.    
It is known, however, that cisplatin and carboplatin have a high affinity for sulfur-
containing biological molecules, such as methionine, glutathione and sulfur 
containing proteins. These interactions have been associated with toxic side effects, 
detoxification and resistance mechanisms, as well as with delivery of active species to 
the cell for ultimate binding to DNA.23a,29,30,31  
In the case of ruthenium, it has been found that [(6-bip)Ru(en)Cl][PF6] (bip = 
biphenyl, en = ethylenediamine) reacts slowly with L-Cys, L-Met and L-His in water 
at 310 K to partial (2250%) completion.32,33 Comparison of the equilibrium 
constants measured suggested that the affinity of the [(6-bip)Ru(en)]2+ moiety for 
these amino acids decreases in the order L-Cys > L-Met > L-His.34 The observed 
reactions were largely suppressed in the presence of 0.1 M NaCl indicating that these 
amino acids may not be able to inactivate the complex in blood plasma or in cells.30 
The low reactivity of these amino acids towards [(6-bip)Ru(en)Cl][PF6] may be the 
reason for low toxic side effects of this and related ruthenium-arene complexes.35 
These interactions cannot impede the transport and delivery of the drugs to the cancer 
cells and allow at least for some amino acids to act as drug reservoirs for DNA 
ruthenation.33 In stark contrast, ruthenium hexacationic prism reacts with His, which 
binds to Ru(6-p-cymeme) moiety with release of the 2,4,6-tri(pyridin-4-yl)-1,3,5-
triazine and 1,4-benzoquinonato ligands, while it remains intact in the presence of 
Met.36 The resulting (p-cymene)Ru-His complex was found to catalyze oxidation of 
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cysteine to cystine more efficiently than the original complex, and this process may 
play a role in the aniproliferative activity of the complex since amino acids represent a 
significant part of cytosol. Sequence-specific catalytic peptide synthesis with the half-
sandwich ruthenium complex is another example well-documented in the literature.37 
NAMI-A treated with histidine or glutamine at their minimum essential medium 
(MEM) concentrations was shown to result in a reduced uptake by KB carcinoma 
cells presumably because of formation of adducts with these amino acids or 
competition between MEM components and NAMI-A upon transport through the cell 
membrane.38 So reactions with amino acids may also have an impact on intracellular 
chemistry of ruthenium-based drugs.   
In this work we report on the preparation of 8 ruthenium-nitrosyl complexes with Gly, 
L-Ala, L-Val, L-Pro, D-Pro, L-Ser, L-Thr and L-Tyr. As starting material 
Na2[RuCl5(NO)]∙6H2O was used, which was prepared by reaction of RuCl3∙nH2O 
with NaNO2 in the presence of 6 M HCl as reported previously, or 
(nBu4N)2[RuCl5(NO)].
24 Complexes 1−8 were synthesized by boiling 
Na2[RuCl5(NO)]∙6H2O with 1.5 equiv tetrabutylammonium chloride and 1.1 equiv of 
the corresponding amino acid or by reaction of (nBu4N)2[RuCl5(NO)] with AA in n-
butanol or n-propanol with 15 to 38% yields. Compounds 1 and 8 crystallized directly 
from the reaction mixture after its completion. All other complexes were obtained by 
evaporating the solvent under reduced pressure and re-crystallization of the residue 
from water at room temperature over 96 h on average. ESI mass spectra measured in 
positive ion mode showed a peak at m/z 242 due to nBu4N
+, while those measured in 
negative ion mode showed strong peaks at m/z 312, 324, 353, 351, 351, 342, 355 and 
419 for 1−8, respectively, attributed to [Ru(NO)Cl3(AA−H)]
−. Other signals of 
moderate intensity usually found in the mass spectra were assigned to 
[RuCl2(AA−H)(NO)−2H]
− and [RuCl(AA−H)(NO)−3H]−. Coordination of an amino 
acid to ruthenium in [RuCl5(NO)]
2− leads to a shift of stretching vibration (NO) from 
1902 cm−1 to 1837−1852 cm−1 for 1−8. All complexes are diamagnetic. The number 
of proton resonances in 1H NMR spectra of 1−8 in DMSO-d6 is in accordance with 
the proposed structures for these compounds (see Chart 1 and experimental section).   
 
X-ray Crystallography. As reported for osmium-nitrosyl complexes with Gly, L-Pro 
and D-Pro,13 three isomeric structures are theoretically possible for 
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[RuCl3(AA−H)(NO)]
− (AA = Gly, L-Ala, L-Val, L-Pro, D-Pro, L-Ser, L-Thr and L-Tyr 
acting as bidentate ligands): one fac-isomer with three chlorido ligands coordinated to 
ruthenium in facial configuration and two others with three chlorido ligands bound to 
central atom in meridional fashion. In the first hypothetical meridional isomer NO is 
located in trans position to the N atom of the amino acid, while in the second NO is 
bound in trans position to the carboxylic oxygen atom of the AA ligand. According to 
X-ray crystallography all studied compounds (18) have a similar ionic crystal 
structure, which is built up from coordination anions [RuCl3(AA−H)(NO)]
− and 
tetrabutylammonium cations. No co-crystallized solvent has been found in the crystals 
of compounds studied, except the structures 2 and 6, which contain some statistically 
distributed water molecules. The results of X-ray diffraction studies of complexes 1−8 
together with atom numbering schemes are shown in Figures 1−3. The 
crystallographic data and refinement details are given in Tables 1 and 2, while 
selected geometrical parameters in Table 3. The asymmetric part in 6 and 7 contains 
two, while in 2 six chemically identical but crystallographically independent 
cation/anion pairs. Figures 1b, 3a and 3b show the structures of only one asymmetric 
component in the unit cell. 
 
Figure 1. ORTEP drawings of the complex anion [RuCl3(GlyH)(NO)]
− in 1 (a), 
[RuCl3(L-AlaH)(NO)]
− in 2 (b), and [RuCl3(L-ValH)(NO)]
− in 3 (c) with atom 
labeling. The thermal ellipsoids are drawn at 50% probability level. 
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Table 1. Crystal Data and Details of Data Collection for complexes 1−4. 
Complex 1 2 3 4 
empirical formula  C18H40Cl3N3O3Ru C19H42.34Cl3N3O3.17Ru C21H46Cl3N3O3Ru C21H44Cl3N3O3Ru  
Fw 553.95 570.98 596.03 594.01 
space group Pna21 P21 P212121 P212121 
a, [Å] 10.1942(5) 15.3062(8) 8.6937(8) 10.2263(4) 
b, [Å] 16.8268(9) 17.0885(8) 13.8069(12) 15.6517(6) 
c, [Å] 15.6678(8) 31.3660(16) 22.711(2) 17.9281(7) 
β, [°]  91.371(3)   
V [Å3] 2687.6(2) 8201.7(7) 2726.1(4) 2869.55(19) 
Z 4 12 4 4 
l [Å]  0.71073 0.71073 0.71073 0.71073 
calcd, [g cm
−3] 1.369 1.387 1.452 1.375 
crystal size, [mm3] 0.08 × 0.07 × 0.05 0.20 × 0.15 × 0.05 0.15 × 0.05 × 0.05 0.20 × 0.18 × 0.10 
T [K] 293(2) 100(2) 100(2) 120(2) 
, [mm−1] 0.902 0.890 0.895 0.850 
R1
a 0.0321 0.0566 0.0634 0.0147 
wR2
b 0.0844 0.1346 0.1656 0.0418 
Flack parameter −0.02(5) 0.02(3) 0.01(8) 0.015(16) 
GOFc 1.001 1.132 1.092 1.025 
 
a R1 = ||Fo|  |Fc||/|Fo|. 
b wR2 = {[w(Fo
2  Fc
2)2]/[w(Fo
2)2]}1/2. c GOF = {[w(Fo
2  Fc
2)2]/(n  p)}1/2, where n is the number of reflections and p is the total number of 
parameters refined. 
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Table 2. Crystal Data and Details of Data Collection for Complexes 5−8. 
Complex 5 6 7 8 
empirical 
formula  
C21H44Cl3N3O3Ru  C19H42.15Cl3N3O4.08Ru C20H44Cl3N3O4Ru C25H46Cl3N3O4Ru 
Fw 594.01 585.33 598.00 660.07 
space group P212121 P1 P21 P212121 
A, [Å] 10.1919(19) 9.7963(4) 12.6677(12) 9.9542(3) 
B, [Å] 15.628(3) 10.7133(4) 10.7195(10) 17.1180(6) 
C, [Å] 17.930(4) 13.6446(6) 20.253(2) 17.8215(6) 
, [°]  75.440(2)   
, [°] 2855.9(10) 85.146(2) 102.943(5)  
, [°] 4 79.953(2)   
V [Å3] 0.71073 1363.52(10) 2680.3(4) 3036.71(17) 
Z 1.382 2 4 4 
l [Å] 0.30 × 0.05 × 0.03 0.71073 0.71073 0.71073 
calcd, [g cm
−3] 120(2) 1.426 1.482 1.444 
crystal size, 
[mm3] 
0.854 0.15 × 0.10 × 0.08 0.30 × 0.10 × 0.06 0.20 × 0.10 × 0.07 
T [K] 0.0539 100(2) 100(2) 120(2) 
, [mm−1] 0.1326 0.896 0.913 0.814 
R1
a 0.05(6) 0.0211 0.0430 0.0318 
wR2
b 1.010 0.0508 0.1110 0.0816 
Flack parameter  0.01(1) 0.06(2) 0.01(3) 
GOFc  1.003 1.065 1.003 
 
a R1 = ||Fo|  |Fc||/|Fo|. 
b wR2 = {[w(Fo
2  Fc
2)2]/[w(Fo
2)2]}1/2. c GOF = {[w(Fo
2  Fc
2)2]/(n  p)}1/2, where n is the number of reflections and p is the total number of 
parameters refined. 
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Table 3. Selected bond distances (Å) and bond angles in 18. 
Atom1Atom2 1 2
a 3 4 5 6b 7b 8 
RuO1 2.001(3) 2.009(5), 1.993(9) 1.997(5) 1.998(1) 1.988(4) 2.008(2), 2.011(3) 2.011(3), 2.009(1) 2.019(3) 
RuN1 2.051(4) 2.078(6), 2.073(4) 2.097(6) 2.107(2) 2.132(6) 2.068(1), 2.074(7) 2.078(3), 2.086(8) 2.077(3) 
RuN2 1.702(4) 1.707(6), 1.714(3) 1.731(7) 1.725(2) 1.726(6) 1.7256(17), 1.7249(7) 1.732(4), 1.729(3) 1.730(3) 
N2O3 1.149(6) 1.178(8), 1.164(7) 1.158(8) 1.147(2) 1.141(7) 1.149(2), 1.1485(5) 1.145(5), 1.147(2) 1.137(3) 
RuCl1 2.361(2) 2.376(2), 2.367(3) 2.363(2) 2.3756(4) 2.383(2) 2.3724(4), 2.374(1) 2.365(1), 2.369(4) 2.3771(7) 
RuCl2 2.361(2) 2.370(2), 2.381(6) 2.376(2) 2.3803(4) 2.368(2) 2.3539(4), 2.36(1) 2.367(1), 2.3664(9) 2.3713(8) 
RuCl3 2.380(1) 2.364(2), 2.360(5) 2.374(2) 2.3636(5) 2.383(2) 2.3789(4), 2.37(3) 2.376(1), 2.371(4) 2.3732(6) 
Atom1Atom2 
Atom3 
        
O1RuN1 80.1(1) 80.0(2), 81.0(4) 80.5(2) 80.67(5) 81.4(2) 79.35(6), 79.2(1) 80.0(1), 79.7(3) 81.28(9) 
RuN2O3 179.1(5) 171.9(6), 176(1) 177.7(6) 176.52(16) 176.4(6) 178.30(15), 177.5(9) 174.1(3), 174.8(7) 179.4(3) 
Cl2RuCl3 172.77(5) 173.71(7), 173.1(5) 173.96(8) 174.90(2) 175.37(7) 172.42(2), 172.9(5) 173.93(4), 173.1(6) 172.74(3) 
aParameters for one of the six crystallographically independent complex anions and average values are quoted. bParameters for one of the two 
crystallographically independent complex anions and average values are quoted.
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Figure 2. ORTEP drawings of the complex anion [RuCl3(L-ProH)(NO)]
− in 4 (a), 
and [RuCl3(D-ProH)(NO)]
− in 5 (b) with atom labeling. The thermal ellipsoids are 
shown at 50% probability level. 
 
 
Figure 3. ORTEP drawings of the complex anion [RuCl3(L-SerH)(NO)]
− in 6 (a), 
[RuCl3(L-ThrH)(NO)]
− in 7 (b), and [RuCl3(L-TyrH)(NO)]
− in 8 (c) with atom 
labeling. The thermal ellipsoids are shown at 50% probability level. 
 
Each ruthenium atom in 18 adopts a slightly distorted octahedral coordination 
geometry, being coordinated by (AAH) nitrogen atom and carboxylate oxygen 
donor, one nitrosyl and one chlorido ligands in the equatorial plane and two Cl  
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ligands in axial positions. Three chlorido ligands are bound meridionally with the 
average distances RuCl at 2.37 Å. The NO ligand is coordinated almost linearly to 
ruthenium on trans position to the carboxylic oxygen atom of the (AAH) ligand 
with the RuO bond length of about 1.71 Å (see Table 3). The equatorial coordination 
plane is practically planar. The maximum deviation from the mean-square plane in all 
structures does not exceed 0.03 Å. In the structures 1 and 8 the five-membered 
chelate ring formed upon the coordination of (AAH) is almost planar, while in all 
other cases it adopts a half-chair conformation. Thus, in 2, 3, 6 and 7 the angle 
between Ru1O1C2C1 and Ru1N1C1 planes is equal to 24.8° 18.9°, 29.8° 24.6°, while 
between Ru1O1C4C5 and Ru1N1O1 in 4 and 5 to 17.1°, 17.5°, respectively. As 
found in earlier reported osmium complexes,13 the two chiral centers located on C1 
and N1 atoms have the same configuration SCSN and RCRN in 4 and 5, respectively. 
The configuration of asymmetric atoms C1 and C3 of L-Thr is also preserved in the 
complex 7. Selected bond lengths and angles summarized in Table 3 suggest that 
there are no marked geometrical parameter variations among the complexes 18. 
 
There are different groups which can play the role of potential proton donors or 
proton acceptors in the crystal structures 18. The relevant hydrogen bonding 
parameters are collected in Table S1. The common crystal structure motif for 18 is 
determined by the parallel packing of one-dimensional polymeric chains, assembled 
via hydrogen bonding of the complex anions. The perspective views of these 
supramolecular architectures are shown in Figures S1S4. These chains are of four 
types depending on the nature of hydrogen bonding interactions. Figure S1 shows 
infinite chains formed in crystals of 13 via NHCl contacts. Polymeric chains in 
complexes 46 are built up via H-bonds of two types NHO and NHCl as shown 
in Figure S2, while those in complexes 7 and 8 shown in Figures S3 and S4 are 
formed via interactions of the types NHO, OHO and NHCl, OHO, 
respectively. Note, that all possibilities for hydrogen bonding formation are exhausted 
in 18.    
 
The diamagnetic behavior of 18, the NO wavenumbers and the linearity of RuNO 
group provide strong evidence for the formulation {Ru(NO)}6 containing RuII (S = 0) 
bound to NO+ (S = 0) or RuIII (S = ½) coupled antiferromagnetically to NO0 (S = ½).  
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Electrochemistry. The redox properties of complexes 28 have been investigated by 
cyclic voltammetry at a glass carbon electrode in a 0.10.2 M [nBu4N][BF4]/CH3CN 
solution at 25 °C. For 37 similar electrochemical behavior was observed as shown in 
Figures S5−S8. The compounds show one to three irreversible oxidation waves with 
peak potential values higher than 1.6 V vs. SCE (Table 4). At these potentials, the 
ruthenium(II) ion is usually oxidized.39 The processes are irreversible due to chemical 
reactions that follow the electron transfer(s). The oxidation of the metal-bound amino 
acid is largely depending on the experimental conditions.40 Dissociation of the amino 
acid from ruthenium results in the formation of electrode deposit. This was 
encountered upon several coulometry experiments performed. The number of 
electrons involved in all the oxidation waves (determined by coulometry or with the 
use of the Fc+/Fc couple as reference) gave generally an apparent electron number napp 
= 3. A similar value was found for [Os(NO)Cl3(AA)]
 (AA = amino acid), with one 
irreversible electron transfer followed by one reversible process.13 For osmium 
complexes, the peak separation was dependent on the nature of the coordinated amino 
acid. In addition, the reaction [Os(NO)]6  [Os(NO]5, generally reversible or quasi-
reversible, could also be identified. Here, all the processes are irreversible and the 
accurate determination of the peak potential values depends on the degree of the 
overlapping of the oxidation waves. In particular, for 3 (Figure S5) a more distinct 
separation of the oxidation waves (at ca. 1.90 and 2.30 V vs. SCE) is observed than 
for 6 (1.80 and 1.87 V vs. SCE). Taking all this into account we suggest that the 
anodic waves can be attributed to both the oxidation of ruthenium ion and the 
oxidation of the amino acid. Upon reduction we observe a one-electron irreversible 
wave at ca. 0.8 V vs. SCE (except for 3 and 8). Note that more positive values were 
seen for related osmium complexes.13 This reduction process presumably takes place 
on the metal center and is followed by chemical transformations. For 3 the general 
pattern of reduction peaks seems to be dependent on the state of the electrode area 
(see Figure S5).  
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Table 4. Cyclic voltammetric dataa for complexes 28.  
Compound Oxidation peaks Reduction peaksb 
2 d   −0.79 
3 1.8sh 1.90 2.28 −1.31 
4 1.63c   −0.79 
5 1.68c   −0.82 
6 1.8sh 1.87  −0.80 
7 1.8sh 1.91  −0.83 
8 d   −2.25 
a Potential values in Volt  0.02 vs SCE, in a 0.10.2 M [nBu4N][BF4]/CH3CN solution, at a GC 
working electrode, determined by using the [Fe(5-C5H5)2]
0/+ redox couple (E1/2
ox = 0.525 V vs 
SCE)41,42 as internal standard at a scan rate of 100 mVs1; the values can be converted to the NHE 
reference by adding +0.245 V. bdetermined in the experiment with several cycles of potential; cin 
comparison with the ferrocene these values are close. d no clear oxidation wave was observed; sh = 
shoulder. 
 
UVvis and CD spectra. The complexes possess fairly similar UV−vis spectra with a 
well-defined λmax at 452 nm (Figure 4).  
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Figure 4. CD (a) and UV−vis (b) spectra of the studied (nBu4N)[RuCl3(AAH)(NO)] 
complexes at pH 7.40 [ccomplex = 50 µM;
 0.02 M phosphate buffer; 0.1 M KCl; T = 298 
K]. 
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CD spectra of the complexes of the L-amino acids show similarities as well, namely 
negative peaks with λmax at ~ 440 and 313 nm, while the complex of D-Pro shows 
positive peaks at the same wavelengths. 
  
Hydrolytic stability, lipophilicity and co-incubation with sodium ascorbate. The 
hydrolytic stability of complex 8 was monitored in aqueous medium buffered at pH 
7.4, 0.1 M KCl by 1H NMR spectroscopy over 24 h. Chemical shifts and shape of all 
peaks remained unchanged within this time frame (see Figure S9). In addition a 
solution of complex 8 in 10% D2O/H2O mixture in non-buffered medium (pH = 5.86) 
showed the same NMR spectra as solutions buffered at pH 7.4. Hydrolytic stability of 
complexes 18 were further investigated by UV−vis spectroscopy (vide infra). 
 
All the prepared complexes were found to be moderately water soluble and stable in 
solution within the time frame of the measurements (5.5 h), since the normalized 
UV−vis spectra recorded after the partitioning were identical with the original ones. It 
is noteworthy that hydrolysis of complexes 5 and 8 is negligible over 24 h in the 
presence of 0.1 M KCl or in its absence as illustrated in Figure 5. 
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Figure 5. Time dependence of absorbance values of (Bu4N)[RuCl3(AAH)(NO)] 
complexes, where AA = D-Pro and L-Tyr recorded at 250 nm at pH 7.40 [ccomplex = 
0.25 mM; 0.02 M HEPES; T = 298.0 K]. 
 
The logD7.4 values of the complexes were determined by the traditional shake-flask 
method in n-octanol/buffered aqueous solution at pH 7.4 by analysis of the UV−vis 
spectra of the aqueous phases before and after separation (Figure S10, Table 5). 
Results revealed the fairly hydrophilic character of all the complexes studied. The 
logD7.4 values for the complexes increase in the following order: Gly (1) < L-Ser (6), 
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L-Thr (7), L-Ala (2) < D/L-Pro (5/4) < L-Tyr (8), L-Val (3) corresponding well to the 
expectations based on the hydrophilicity of the side chains of the coordinated amino 
acids. On the other hand the presence of chloride ion does not alter significantly the 
lipophilicity of the complexes (Table 5). 
The aqueous stability of compounds 1, 4, 5 and 8 was also confirmed by ESI mass 
spectrometry. Mass spectra recorded in the negative ion mode revealed [RuCl3(AA –
 H)NO] as the major species (Figures S11–S13) in all four incubations over 24 h, 
while TBA was the only mass signal in the positive ion mode. Similar mass spectra 
were observed for the co-incubation with 4 equiv sodium ascorbate, a potent 
biological reducing agent. These results largely parallel the findings with analogous 
osmium-nitrosyl complexes with amino acids, which were also stable in water.13 In 
the present study, however, an additional mass signal was assigned to [RuCl(AA –
 H)NO – 2H] and probably stems from the spraying process. The simultaneous 
cleavage of two HCl molecules from the parent mass signal during ionization 
indicates that the ruthenium compounds might be activated by hydrolysis. This would 
also be in line with the increased antiproliferative activity of the [RuCl(AA – H)NO] 
series compared to the osmium counterparts. Obviously, compound 1 does only have 
4 hydrogen atoms stemming from the coordinated Gly–H. We performed ESI-MS 
experiments of 1 in D2O and H2O, respectively, in order to investigate, which 
hydrogens are abstracted to provide the negative charge of this gas-phase compound 
(Figure 6). Dissolution of 1 in D2O leads to the exchange of the labile –NH2 to –ND2 
and the resulting compound [RuCl3(N,N-d2-Gly – H)NO]
 (m/z 314.74 compared to 
m/z 312.72 of 1) was analyzed. As can be seen in Figure 6 in a first step DCl is 
cleaved from the parent ion following the deprotonation of the coordinated amine. 
The cleavage of HCl in the second step suggests imine formation.   
Incubation with sodium ascorbate did not induce ligand release over 24 h. Note that 
related ruthenium-nitrosyl complexes with azole heterocycles reacted quantitatively 
with sodium ascorbate within several hours.15 
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Figure 6. ESI mass spectra of 1 in D2O (A) and H2O (B) are shown. Dissolution of 1 
in D2O leads to the exchange of the labile hydrogen atoms of the amino group by 
deuterium introducing two neutrons in the compound increasing the molecular mass. 
The mass-to-charge ratio of the fragments indicates the position of H/D abstraction 
(C).  
 
Inhibition of cancer cell growth. The in vitro anticancer activity of complexes 1−8 
was assessed in human cancer cell lines CH1 (ovarian carcinoma), SW480 (colon 
carcinoma) and A549 (nonsmall cell lung carcinoma) by means of the colorimetric 
MTT assay, yielding the IC50 values listed in Table 5. All compounds show a higher 
effect in the generally more chemosensitive CH1 cells (IC50: 7.5–27 µM) than in 
SW480 cells (IC50: 20–71 µM) and the generally more chemoresistant A549 cells 
(IC50: > 100 µM). With regard to variation of the amino acid ligand, differences 
between IC50 values within each of the cell lines CH1 and SW480 are all smaller than 
fourfold. In CH1 cells, the IC50 is 3.6 times higher for the glycinato complex 1, which 
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is the most hydrophilic compound, than for the L-valinato complex 3, which is the 
most hydrophobic compound. The L-prolinato (4) and D-prolinato (5) analogs show 
differences in antiproliferative activity, with the latter being more active than the 
former by factors of 1.5 and 2.7 in CH1 and SW480 cells, respectively. Overall, 
complex 5 shows the strongest growth inhibitory effect in all three cancer cell lines. 
The antiproliferative activity of these ruthenium complexes is particularly remarkable 
in comparison with osmium analogs published previously.13 The ruthenium complex 
(nBu4N)[RuCl3(GlyH)(NO)] (1) turned out to be more active than corresponding 
osmium analog (n-Bu4N)[Os(NO)Cl3(Gly)] with a maximum factor of 12 in CH1 cells 
(3.6 and 3.2 in SW480 and A549 cells, respectively). In the mentioned publication the 
(n-Bu4N)[Os(NO)Cl3(L-Pro)] and (n-Bu4N)[Os(NO)Cl3(D-Pro)] complexes did not 
show pronounced activity and no differences between isomers. In contrast, the 
complexes (nBu4N)[RuCl3(L-ProH)(NO)] and (nBu4N)[RuCl3(D-ProH)(NO)] 
presented here show pronounced effects and a slight dependence on L-/D-isomerism. 
The D-isomer is 11-fold and 14-fold more active in CH1 and SW480 cells, 
respectively, whereas the L-isomer is 5.7-fold and 4.4-fold more active than the 
respective osmium analog. A synopsis of all comparisons reveals that the impact of 
changing the metal center on cytotoxic potency is much bigger than that of varying 
the amino acid ligand. 
Table 5. In vitro anticancer activity of the compounds 1−8 and three osmium 
analogues 1*, 4* and 5* in human ovarian (CH1), colon (SW480) and non-small cell 
lung (A549) carcinoma cell lines and logD7.4 values for the complexes; 50% 
inhibitory concentrations (means ± standard deviations), obtained by the MTT assay 
(exposure time 96 h), logD7.4 values were estimated in 0.02 M HEPES; T = 298.0 K. 
                 IC50 values  SD (µM)       Partition coefficients 
Complex A549 CH1 SW480 logD7.4 logD7.4
[a] 
1 196  27 7.5  1.2 39  3 2.04  0.08  
2 >320 12  2 47  3 1.63  0.08 1.47  0.11 
3 >320 27  3 53  2 1.13  0.02 1.31  0.07 
4 >320 20  3 54  10 1.55  0.08  
5 108  5 13  1 20  3 1.43  0.08  
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6 >320 13  2 63  10 1.77  0.12  
7 >320 23  2 71  15 1.75  0.02  
8 >320 17  3 38  12 1.16  0.02  
1*[b] 629  13 89  11 140  36   
4*[b] >320 114  37 237  47   
5*[b] >640 148  38 274  40   
[a] in the presence of 0.1 M KCl; [b] data taken from ref. 13. 
 
Conclusions 
Reactions of potential anticancer drugs with amino acids have been studied by 
different groups,32,43,44 but mainly in solution by 1H NMR spectroscopy without 
isolation of the resulting products. We have succeeded to prepare a series of 
ruthenium-nitrosyl complexes with amino acids of the general formula 
(nBu4N)[RuCl3(AAH)(NO)], where AA = Gly, L-Ala, L-Val, L-Pro, D-Pro, L-Ser, L-
Thr and L-Tyr, in addition to two complexes documented in the literature with L-His 
and L-Met, namely [RuCl2(L-His)(NO)],
10 and [RuCl2(L-Met)(NO)].
11 X-ray 
crystallographic studies have shown that in crystal structures of 18, like in the 
previously reported osmium counterparts (nBu4N)[OsCl3(AAH)(NO)],
13 where AA 
= Gly, L-Pro and D-Pro, the carboxylate oxygen is a more preferred ligand in trans 
position to the coordinated nitrosyl ligand than the chloride ligand, secondary or 
primary amine. Likewise, the only isomer isolated from reactions of [RuCl5(NO)]
2 
with eight amino acids is mer(Cl),trans(NO,O)-(nBu4N)[OsCl3(AAH)(NO)]. The 
results of the present study demonstrate that aminoacids used in this work are 
potential biological ligands for ruthenium-nitrosyl-based drug candidates in the blood 
serum and in the cytosol. A comparison with previously reported osmium analogues 
reveals a favorable influence of ruthenium on antiproliferative activity in human 
cancer cell lines in vitro, probably via hydrolysis pathways, although the cytotoxicity 
of ruthenium complexes with amino acids is either moderate or low depending on 
human cancer cell line. Whether this is a result of their low uptake into the cells 
taking into account their reduced lipophilicity or effective efflux as a part of 
detoxification mechanism, this should be clarified in ongoing research. Variation of 
the amino acid ligand has an even smaller impact on this activity within the range of 
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amino acids employed. Nevertheless, the synthesis of ruthenium- and osmium-nitrosyl 
complexes with other amino acids, and, in particular, Met, His and Cys, deserves 
attention as this will provide the opportunity to investigate their biological effects, 
which may differ from those studied in the present work. Collectively this may help in 
elucidating the mechanism of action of ruthenium and osmium-nitrosyl complexes 
with azole heterocycles. Activation of amino acidate ligands upon coordination to the 
metal may lead to specific intracellular chemistry and the resulting species may play a 
major role in either detoxification or therapeutic activity. According to other authors45 
oxidation of the sulfur atom of the tripeptide glutathione afforded sulfenato 
complexes, and binding to DNA mediated by these complexes may play a role in the 
mechanism of action of RM175. Similar behavior of coordinated cysteine has not 
been documented, but may be also envisaged.       
 
Supporting Information 
One-dimensional chains in a) 1, b) 2 and c) 3 assembled via N−H∙∙∙Cl hydrogen 
bonding (Figure S1), one-dimensional chains assembled via N−H∙∙∙O hydrogen 
bonding in a) 4 and b) 5 (Figure S2), one-dimensional chains assembled via N−H∙∙∙O 
and O−H∙∙∙Cl hydrogen bonding in a) 6, b) and c) 7 (two independent supramolecular 
chains) (Figure S3), one-dimensional supramolecular chains assembled via N−H∙∙∙Cl 
and O−H∙∙∙O hydrogen bonding in 8 (Figure S4), Cyclic voltammograms with several 
cycles of potential for 3, 5, 6 and 7 at 100 mV/s on glass carbon electrode (Figures 
S5S8), hydrogen bonding  parameters in 18 (Table S1), crystallographic data in 
CIF format. 1H NMR and mass spectra of 1, 4, 5 and 8 are shown in Figures S9, 
S11S13 and logD7.4 values of the complexes 18. 
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